Like other business around the world, Starpharma continues to closely monitor the COVID-19 pandemic and its impact.
The health and safety of our people, trial patients and VivaGel® customers is paramount. Starpharma has implemented a broad program of measures to protect the health and safety of our staff and clinical trial patients, and to ensure product supply to customers.
Starpharma has a COVID-19 Safe Plan in place. Starpharma’s laboratory and internal operations have continued to operate under this COVID-19 safe plan, with minimal disruption. The COVID-19 safe plan includes mitigation actions in specific areas including stringent hygiene, cleaning, physical distancing, record keeping and response preparation in the event of a suspected or confirmed COVID‑19 case.
Starpharma’s management team continues to monitor the situation and update its policies based on current medical advice and Government directives, as required.
Read about how Starpharma is contributing to the fight against COVID-19 here